Roche/AbbVie's Venclexta Meets Endpoint in CLL Study; We Remain Bullish on Drug's Potential
Roche and partner AbbVie announced that the combination of blood cancer drugs Rituxan and Venclexta in relapsed/refractory chronic lymphocytic leukemia extended progression-free survival over the standard of care (Rituxan plus bendamustine) in the Murano study. While details of the study will be presented at a future meeting (potentially the annual meeting of the American Society of Hematology in December), we’re bullish on the ability of this combination--and the Gazyva/Venclexta combination be...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.